11选5多乐彩大赢家:Fluorescent Conjugated CD19 Protein (FITC / PE)

江西体彩11选5多乐彩走势图今天 www.phcnlx.com.cn CD19 is the most widely used hematologic malignancy target in CAR-T cell therapy and good therapeutic effects have been achieved in clinical trials of hematological malignancies such as B-ALL, CLL, FL, DLBCL and MCL. Fluorescent conjugated CD19 proteins are reliable reagents for detection of CAR expression. This can simplify detection procedures and save detection time. We offer FITC and PE conjugated CD19 proteins. They are good tools for detection of anti-CD19 CAR expression in samples by flow cytometry.

FITC Conjugated CD19 Protein
Catalogue No. Product description
11880-H08H-F Human CD19 Protein (FITC conjugated)
Detection of CD19-CAR expression by flow cytometry

Flow cytometric analysis of FITC-CD19 protein on CD19-CAR transfected 293 cells
PE Conjugated CD19 Protein
Catalogue No. Product description
11880-H08H-P Human CD19 Protein (PE conjugated)
Detection of CD19-CAR expression by flow cytometry

Flow cytometric analysis of PE-CD19 protein on CD19-CAR transfected 293 cells

Biotinylated CD19 protein & Unconjugated CD19 protein

Biotinylated CD19 protein

Catalogue No. Product description Species Tag Expression host Size
11880-H08H-B Biotinylated CD19 Protein Human His Tag HEK293 Cells 20μg / custom size

Unconjugated CD19 Protein

Catalogue No. Species Tag Expression host Size
11880-H02H Human Fc Tag HEK293 Cells 20μg / 50μg
11880-H08H Human His Tag HEK293 Cells 20μg / 50μg
11880-H08B Human His Tag Baculovirus-Insect Cells 20μg / 50μg
90051-C02H Cynomolgus Fc Tag HEK293 Cells 20μg / 100μg
90051-C08H Cynomolgus His Tag HEK293 Cells 20μg / 100μg
50510-M08H Mouse His Tag HEK293 Cells 10μg / 20μg / 50μg

Products list of hematologic malignancies target proteins

In addition to CD19, molecules such as CD20, CD22, CD30, IL3RA are also hot targets for hematologic malignancies research, especially for CD19-negative hematologic malignancies.
We offer biotinylated proteins of the following targets. If you're interested in, please contact 400-890-9989.

Target Tumor Type
BCMA Multiple myeloma
IL3RA Myeloid malignancies
CD138 Multiple myeloma
CD20 Leukemia, Lymphoma, Multiple myeloma
CD22 / Siglec-2 B-cell lymphoma
CD30 Lymphoma
CD33 / Siglec-3 Myeloid malignancies
CD38 Acute myeloid leukemia, Multiple myeloma
CD5 / Leu-1 T cell acute lymphoblastic lymphoma
CD56 Acute myeloid leukemia
NKG2D ligand 1 / ULBP1 A variety of hematological malignancies
NKG2D ligand 2 / ULBP1 A variety of hematological malignancies
IL1R3 Chronic myeloid leukemia
ROR1 Non-small cell lung cancer, Breast cancer, Leukemia

CD19 research references

? De Oliveira, S. N., Wang, J., Ryan, C., Morrison, S. L., Kohn, D. B., & Hollis, R. P. (2013). A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors. Journal of translational medicine, 11(1), 23.
? Zah, E., Lin, M. Y., Silva-Benedict, A., Jensen, M. C., & Chen, Y. Y. (2016). T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer immunology research, 4(6), 498-508.
? Maude, S. L., Teachey, D. T., Porter, D. L., & Grupp, S. A. (2015). CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood, 125(26), 4017-4023.